08048035996
Erlonat 150 mg Good Quality Tablets to UK - Birmingham | Phoenix Exim | Trusted Exporter

1. General Information

Erlonat 150 mg Tablet is an oral targeted cancer medicine containing erlotinib 150 mg. It is prescribed for specific cancer types where treatment with an EGFR-targeted medicine is appropriate. The medicine should be used strictly under the supervision of an oncologist.

Product name: Erlonat 150 mg Tablet
Active ingredient: Erlotinib 150 mg
Manufacturer/Marketer: Natco Pharma Ltd.
Dosage form: Film-coated tablet
Route: Oral
Prescription status: Prescription medicine
Therapeutic class: Anticancer / Tyrosine kinase inhibitor


2. Product Information

Erlonat 150 mg is an EGFR-targeted therapy. Erlotinib blocks signaling through the epidermal growth factor receptor (EGFR), which can contribute to the growth and multiplication of certain cancer cells.

The 150 mg strength is particularly used in certain patients with advanced or metastatic NSCLC when appropriate according to the patient's cancer characteristics and physician's assessment. Erlotinib is also used with other treatment for certain cases of advanced pancreatic cancer.


3. Uses of Erlonat 150 mg Tablet

Erlonat 150 mg may be prescribed for:

  • Certain non-small-cell lung cancers (NSCLC), particularly cancers where EGFR-targeted treatment is appropriate.
  • Advanced or metastatic NSCLC in selected patients.
  • Advanced pancreatic cancer, where erlotinib may be used in combination with other anticancer treatment such as gemcitabine.

The exact indication depends on the patient's cancer type, stage, molecular testing and previous treatment.


4. Benefits of Erlonat 150 mg

Erlonat may provide the following therapeutic benefits when appropriately prescribed:

  • Provides targeted anticancer treatment rather than nonspecific cytotoxic activity.
  • Helps inhibit EGFR signaling involved in the growth of certain cancer cells.
  • May slow the progression of appropriately selected EGFR-driven cancers.
  • Can be administered orally, making it a convenient treatment option for eligible patients.

The response to erlotinib varies between patients, and it is not suitable for every type of lung or pancreatic cancer.


5. Side Effects of Erlonat 150 mg

Possible side effects include:

  • Skin rash
  • Diarrhea
  • Dry or irritated skin
  • Loss of appetite
  • Tiredness or weakness
  • Nausea
  • Abdominal discomfort
  • Mouth sores
  • Headache

Some adverse reactions can be serious. Patients should contact their treating doctor promptly if they develop severe or persistent symptoms.


6. Common Side Effects

Commonly reported effects include rash, diarrhea, stomach/abdominal discomfort, tiredness and headache.

Skin reactions are relatively characteristic of EGFR inhibitors. Your oncologist may recommend supportive treatment if these occur.


7. How to Use Erlonat 150 mg

Take Erlonat exactly as prescribed by your oncologist.

  • It is generally taken orally once daily, according to the prescribed regimen.
  • Take it on an empty stomach, at least 1 hour before or 2 hours after food.
  • Swallow the tablet whole with water.
  • Do not crush, chew or break the tablet unless your healthcare professional specifically instructs you otherwise.
  • Take it at approximately the same time each day.
  • Do not change the dose or discontinue treatment without consulting your oncologist.

8. How Erlonat 150 mg Works

Erlonat contains erlotinib, which is a tyrosine kinase inhibitor.

Some cancer cells use EGFR signaling to receive signals that promote their growth and multiplication. Erlotinib blocks the activity of EGFR and interferes with these growth signals. This can help slow or inhibit the growth of susceptible cancer cells.


9. Safety Advice

Prescription use: Erlonat should only be taken under specialist medical supervision.

Pregnancy: Erlotinib can harm an unborn baby. Inform your doctor if you are pregnant, planning pregnancy or could become pregnant.

Breastfeeding: Discuss breastfeeding with your doctor before starting treatment.

Liver problems: Tell your doctor if you have liver disease or abnormal liver tests, as monitoring may be necessary.

Lung symptoms: Seek urgent medical attention for new or worsening breathing difficulties, cough or fever because serious lung reactions can occur with erlotinib.

Eye problems: Report significant eye irritation, pain, redness or visual changes.

Drug interactions: Tell your doctor about all medicines, supplements and herbal products you take. Certain medicines can affect erlotinib levels.

Smoking: Smoking can reduce erlotinib exposure and may affect treatment; discuss smoking with your oncologist.

Storage: Store according to the product label; commonly, the medicine is stored below 30°C.


10. Frequently Asked Questions (FAQs)

Q1. What is Erlonat 150 mg used for?
Erlonat 150 mg is used for certain types of non-small-cell lung cancer and, in selected treatment regimens, advanced pancreatic cancer.

Q2. What is the composition of Erlonat 150 mg?
It contains erlotinib 150 mg.

Q3. Is Erlonat a chemotherapy medicine?
It is an oral targeted anticancer therapy and belongs to the tyrosine kinase inhibitor class rather than traditional cytotoxic chemotherapy.

Q4. How should Erlonat 150 mg be taken?
It is generally taken once daily on an empty stomach, at least one hour before or two hours after food, as directed by the oncologist.

Q5. Can I stop Erlonat when I feel better?
No. Do not stop cancer treatment without consulting your oncologist.

Q6. Does Erlonat cause skin rash?
Yes. Skin rash is a commonly reported adverse effect of erlotinib.

Q7. Is Erlonat available in different strengths?
Erlotinib products are available in different strengths, including 100 mg and 150 mg; the appropriate strength depends on the prescribed treatment.

Q8. Is Erlonat available without a prescription?
It is a prescription medicine and should be used only under appropriate medical supervision.


11. Substitute for Erlonat 150 mg

Possible alternatives may include other erlotinib 150 mg products or other EGFR-targeted medicines, depending on the patient's diagnosis and molecular profile.

Examples of medicines in the broader EGFR-targeted therapy category include gefitinib and osimertinib, but these are not automatically interchangeable with Erlonat. The appropriate alternative must be selected by the treating oncologist based on EGFR mutation status, cancer type, treatment history, drug interactions and other clinical factors.

Do not switch cancer medicines without medical advice.


12. SEO Keywords

  1. Erlonat 150 mg Tablet
  2. Erlonat 150 mg Tablet exporter
  3. Erlonat 150 mg supplier from India
  4. Erlonat 150 mg wholesale supplier
  5. Erlotinib 150 mg Tablet exporter
  6. Erlotinib 150 mg medicine supplier India
  7. Erlotinib 150 mg oncology medicine exporter
  8. Erlonat 150 mg cancer medicine supplier
  9. Erlonat 150 mg pharmaceutical exporter
  10. Erlonat 150 mg tablets supplier
  11. Erlonat 150 mg exporter from Nagpur India
  12. Erlotinib 150 mg exporter from Nagpur
  13. Erlonat 150 mg B2B medicine supplier
  14. Erlonat 150 mg wholesale pharmaceutical supplier
  15. Erlonat 150 mg export supplier India
  16. Erlonat 150 mg supplier USA
  17. Erlonat 150 mg supplier UK
  18. Erlonat 150 mg supplier Australia
  19. Erlonat 150 mg supplier Canada
  20. Erlonat 150 mg supplier Singapore
  21. Erlonat 150 mg supplier South Korea
  22. Erlonat 150 mg supplier UAE
  23. Erlotinib 150 mg supplier USA
  24. Erlotinib 150 mg supplier UK
  25. Erlotinib 150 mg supplier Australia
  26. Erlotinib 150 mg supplier Canada
  27. Erlotinib 150 mg supplier Singapore
  28. Erlotinib 150 mg supplier South Korea
  29. Erlotinib 150 mg supplier UAE
  30. Phoenix Exim Erlonat 150 mg supplier
  31. Phoenix Exim Erlotinib 150 mg exporter
  32. Phoenix Exim pharmaceutical exporter Nagpur India
  33. Erlonat 150 mg oncology medicine exporter India
  34. Erlonat 150 mg international pharmaceutical supplier
  35. Erlonat 150 mg B2B exporter from India
Aug 14th, 2026 3:16 PM

Keywords